Table 1.
Sociodemographic and clinical characteristics of the patients
| Characteristic | Total n = 178(%) | IG n = 89(%) | CON n = 89(%) | pvalue |
|---|---|---|---|---|
|
Sex |
|
|
|
|
| Male |
75(42%) |
38(43%) |
37(42%) |
0.879 |
| Female |
103(58%) |
51(57%) |
52(58%) |
|
|
Age (years) |
|
|
|
|
| 20-49 |
113(63%) |
56(63%) |
57(64%) |
0.585 |
| 50-69 |
64(36%) |
33(37%) |
31(35%) |
|
| 70-79 |
1(1%) |
0 |
1(1%) |
|
|
Marital status |
|
|
|
|
| Married |
172(97%) |
87(98%) |
85(96%) |
0.406 |
| Single/divorced/widow |
6(3%) |
2(2%) |
4(4%) |
|
|
Education level |
|
|
|
|
| Primary school |
5(3%) |
2(2%) |
3(3%) |
0.808 |
| Junior high school |
18(10%) |
8(9%) |
10(11%) |
|
| Senior high school |
86(48%) |
46(52%) |
40(45%) |
|
| Above college |
69(39%) |
33(37%) |
36(41%) |
|
|
Employment status |
|
|
|
|
| Employed |
131(73%) |
67(75%) |
64(72%) |
0.707 |
| Resigned |
19(11%) |
10(11%) |
9(10%) |
|
| Unemployed |
28(16%) |
12(13%) |
16(18%) |
|
|
Locality |
|
|
|
|
| Urban |
78(44%) |
40(45%) |
38(43%) |
0.763 |
| Rural |
100(56%) |
49(55%) |
51(57%) |
|
|
Primary cancer site |
|
|
|
|
| Nasopharyngeal |
62(35%) |
31(35%) |
31(35%) |
0.989 |
| Breast |
41(23%) |
19(21%) |
22(25%) |
|
| Gynecological cancer (cervical and endometrial) |
31(17%) |
14(16%) |
17(19%) |
|
| Lung |
14(7%) |
7(8%) |
7(8%) |
|
| Others (rectum\lymphoma\glioma etc.) |
30(17%) |
15(17%) |
15(17%) |
|
|
ECOG performance status |
|
|
|
|
| 0 ~ 1 |
170(96%) |
86(97%) |
84(94%) |
0.469 |
| 2 |
8(4%) |
3(3%) |
5(6%) |
|
|
Disease progression |
|
|
|
|
| Advanced |
111(62%) |
53(60%) |
58(65%) |
0.439 |
| Early stage |
67(38%) |
36(40%) |
31(35%) |
|
|
History of operation |
|
|
|
|
| Yes |
87(49%) |
44(49%) |
43(48%) |
0.881 |
| No |
91(51%) |
45(51%) |
46(52%) |
|
|
Radiotherapy dose |
|
|
|
|
| ≥70Gy |
78(44%) |
39(44%) |
39(44%) |
0.894 |
| 50 ~ 70Gy |
97(54%) |
49(55%) |
48(54%) |
|
| <50Gy |
3(1%) |
1(1%) |
2(2%) |
|
|
Brachytherapy |
14(7%) |
6(7%) |
8(9%) |
|
|
Chemotherapy |
|
|
|
|
| None |
52(29%) |
29(33%) |
23(26%) |
0.710 |
| Neoadjuvant |
13(7%) |
6(7%) |
7(8%) |
|
| Concomitant |
77(43%) |
35(39%) |
42(47%) |
|
| Adjuvant |
102(57%) |
50(56%) |
52(58%) |
|
|
Comorbid condition |
|
|
|
|
| None |
158(89%) |
77(87%) |
81(91%) |
0.877 |
| Diabetes |
7(4%) |
4(4%) |
3(3%) |
|
| Hypertension |
14(8%) |
8(9%) |
6(7%) |
|
| Coronary heart disease |
3(2%) |
1(1%) |
2(2%) |
|
| Hepatitis B | 3(2%) | 2(2%) | 1(1%) |
Abbreviations: IG intervention group, CON control group.